Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial

Clinical Infectious Diseases · Published 2026-07-27 · DOI 10.1093/cid/ciag452

Free full text

Authors (20)

Rulan Griesel, Sebastian A Nuñez, Ezequiel Cordova, Alma Minerva Pérez Rios, Verónica Lacal Ridilenir, Clara Lehmann, Jihad Slim, Carmen Busca Arenzana, Jason Szabo, Pedro Cahn, Frank A Post, Amy Pierce, Matthew Pestrak, Jerry L Jeffrey, Nilay Thakkar, Bronagh Shepherd, Veronica Bainbridge, Konstantinos Angelis, Carlye McMillan, Paul Benn

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Griesel, R., Nuñez, S., Cordova, E., et al. (2026). Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag452

Related articles